v3.26.1
REVENUE RECOGNITION
 6 Months Ended
Jun. 30, 2026
Revenue from Contract with Customer [Abstract]  
REVENUE RECOGNITION REVENUE RECOGNITION
a.     Net revenues
The Company’s net revenues by geographic region, based on the patient’s location are summarized as follows:
Three months ended June 30,Six months ended June 30,Year ended Year ended December 31,
 20262025202620252025
United States$102,955 $94,261 $198,911 $187,415 $385,632 
International markets:
Germany23,341 19,074 47,845 37,792 79,407 
France 21,347 18,416 44,225 36,275 76,189 
Japan11,780 9,484 22,023 18,193 37,786 
Other international markets18,205 12,979 33,884 24,916 56,898 
International markets - Total74,673 59,953 147,977 117,176 250,280 
Greater China (1)
5,956 4,591 10,751 9,208 19,441 
Total net revenues$183,584 $158,805 $357,639 $313,799 $655,353 
(1) For additional information, see Notes 12 and 13 to the Consolidated Financial Statements in the 2025 10-K.

The Company's net revenues by performance period are as follows:
Three months ended June 30,Six months ended June 30,Year ended December 31,
 20262025202620252025
Net revenues recognized in the reporting period from performance obligations satisfied in:
Reporting period$174,813 $150,954 $343,986 $296,970 $632,358 
Previous periods8,771 7,851 13,653 16,829 22,995 
Total net revenues$183,584 $158,805 $357,639 $313,799 $655,353 
b.     Contract balances
The following table provides information about trade receivables, unbilled receivables and contract liabilities from contracts with customers:
June 30,
2026		December 31,
2025
 UnauditedAudited
Trade receivables$91,459 $81,648 
Unbilled receivables$7,672 $7,787 
Deferred revenues (short-term contract liabilities)$(16,866)$(15,948)
During the six months ended June 30, 2026 and 2025 and the year ended December 31, 2025 the Company recognized $15,948, $14,225 and $14,225, respectively, which were included in the deferred revenues (short-term contract liability) balance at January 1, 2026 and 2025.